Circulating vascular endothelial growth factor in the normo-and/or microalbuminuric patients with type 2 diabetes mellitus

Acta Diabetologica

Volumn 47, Issue 2, 2010, Pages 119-124

  Kubisz, Peter ^a   Chudý, Peter ^a   Staško, Ján ^a   Galajda, Peter ^a   Hollý, Pavol ^a   Vyšehradský, Robert ^a   Mokán, Marián ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Diabetes mellitus type 2; Endothelial dysfunction; VEGF

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VON WILLEBRAND FACTOR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CREATININE; GLYCOSYLATED HEMOGLOBIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BIOMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; KIDNEY FAILURE; MALE; METABOLIC PARAMETERS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ALBUMINURIA; BLOOD; BLOOD PRESSURE; BODY MASS; GLOMERULUS FILTRATION RATE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; URINE; VASCULAR ENDOTHELIUM;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CARBOXYPEPTIDASE U; CREATININE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952765466     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-009-0127-2     Document Type: Article

References (31)

1. Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003-2017
2. Wolf G, Ziyadeh FN (2007) Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106:26-31
3. Khamaisi M, Schrijvers BF, De Vriese AS et al (2003) The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 18:1427-1430
4. Flyvbjerg A (2000) Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223
5. Chiarelli F, Spagnoli A, Basciani F et al (2000) Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabetes UK Diabet Med 17:650-656
6. Knöbl P, Schernthaner G, Schnack C et al (1993) Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:1045-1050
7. Santilli F, Spagnoli A, Mohn A et al (2001) Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 86:3871-3876
8. Hovind P, Tarnow L, Oestergaard PB et al (2000) Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57(Suppl 75):S56-S61
9. Wasada T, Kawahara R, Katsumori K et al (1998) Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 47:27-30
10. Blann AD, Belgore FM, McCollum CN et al (2002) Vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci 102:187-194
11. Shimada K, Baba T, Neugebauer S et al (2002) Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy. J Diabetes Complications 16:386-390
12. Kim NH, Kim KB, Kim DL et al (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabetes UK Diabet Med 21:545-551
13. Kim NH, Oh JH, Seo JA et al (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 67:167-177
14. Cha DR, Kang YS, Han SY et al (2004) Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 183:183-194
15. Heywood DM, Mansfield MW, Grant PJ (1996) Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 13:720-725
16. Collier A, Rumley A, Rumley AG et al (1992) Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 41:909-913
17. Schmitz A, Ingerslev J (1990) Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med 7:521-525
18. Gabat S, Keller C, Kempe HP et al (1996) Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 25:233-241
19. Inukai T, Fujiwara Y, Tayama K et al (1996) Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 33:99-104
20. Nilsson TK, Hellsten G, Amiral J (1993) Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 4:455-458
21. Yano Y, Kitagawa N, Gabazza EC et al (2003) Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 88:736-741
22. Gruden G, Cavallo-Perin P, Romagnoli R et al (1994) Prothrombin fragment 1 + 2 and antithrombin III-thrombin complex in microalbuminuric type 2 diabetic patients. Diabet Med 11:485-488
23. Leurs PB, Stolk RP, Hamulyak K et al (2002) Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 25:1340-1345
24. Kario K, Matsuo T, Kobayashi H et al (1995) Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114-1120
25. Miccoli R, Giampietro O, Penno G et al (1989) 'Microalbuminuria' in type I (insulin-dependent) diabetic patients with and without retinopathy. Acta Diabetol Lat 26(2):163-170
26. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report. Diabetes Care 26(Suppl 1):S5-S20
27. Tütüncü NB, Gürlek A, Gedik O (2001) Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 38(4):157-161
28. McLaren M, Elhadd TA, Greene SA et al (1999) Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Apll Thromb Haemost 5:21-24
29. Chaturvedi N, Fuller JH, Pokras F et al (2001) Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 18:288-294
30. Sharp PS, Al-Mrayat M, Valabhji J et al (1998) Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologica 41:984-985
31. García de la Torre N, Rubio MA, Bordiú E et al (2008) Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 93(11):4276-4281